There are currently 78 clinical trials in Huntsville, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including Heart Center Research, LLC, Clearview Cancer Institute, Pfizer Investigational Site and Medical Affiliated Research Center Inc. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06029426
Recruiting
This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA 335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA 335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/11/2024
Locations: Neumora Investigator Site, Huntsville, Alabama
Conditions: Major Depressive Disorder
Register for Updates
SYMPHONY-PE Study for Treatment of Pulmonary Embolism
NCT06062329
Recruiting
Evaluation of the Safety and Efficacy of the Symphony Thrombectomy System in the Treatment of Pulmonary Embolism
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/11/2024
Locations: Huntsville Hospital, Huntsville, Alabama
Conditions: Acute Pulmonary Embolism, Thromboembolism, Emboli, Pulmonary, Thrombosis, Thrombus; Embolism, Embolism, Cardiovascular Diseases, Vascular Diseases
Register for Updates
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
NCT06173570
Recruiting
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers is also investigated. The concentration of AZD0780 in blood at specific timepoints is measured, and the safety and tolerability of AZD0780 will be evaluated. There is a follow-up after end of treatment, but expanded ac... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/11/2024
Locations: Research Site, Huntsville, Alabama
Conditions: Dyslipidemia
Register for Updates
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT05097989
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤ 75 years of age) with either LN or IgAN. The study will consist of an up to 6-week Screening Period, a 26-week blinded Initial Evaluation Period, a 24-week blinded Extended Treatment Period, and an Open-label Extension (OLE) Period of up to 2 years. Safety will be monit... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/10/2024
Locations: Research Site, Huntsville, Alabama
Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
Register for Updates
Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)
NCT05966662
Recruiting
This investigational device exemption (IDE) study is to assess the safety and effectiveness of the Shockwave Coronary Intravascular Lithotripsy (IVL) System with the Shockwave C2+ 2Hz Coronary IVL Catheter to treat de novo, calcified, stenotic, coronary lesions prior to stenting.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: Heart Center Research, Huntsville, Alabama
Conditions: Coronary Artery Disease, Myocardial Infarction
Register for Updates
MicroRNA Correlates of Childhood Maltreatment and Suicidality
NCT04923685
Recruiting
This is a research study to find out if childhood trauma and stress are associated with depression or suicidal risk. The study will assess the effects of both short-term and long-term stress on biomarker (e.g. miRNA [MiRNA]) levels. miRNAs are a type of RNA (genetic material that is translated into protein) that are found in throughout the body and blood. They are called microRNA because their size is much smaller than typical RNA molecules. miRNAs are highly responsive to environment. This resp... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/10/2024
Locations: UAB Huntsville Regional Medical Campus, Huntsville, Alabama
Conditions: Major Depressive Disorder, Suicidal Ideation
Register for Updates
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
NCT04894591
Recruiting
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Clearview Cancer Institute, Huntsville, Alabama
Conditions: Extensive-stage Small-cell Lung Cancer
Register for Updates
AMPLATZER PFO Occluder Post Approval Study
NCT03309332
Recruiting
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/08/2024
Locations: Heart Center Research, LLC, Huntsville, Alabama
Conditions: Stroke, Patent Foramen Ovale
Register for Updates
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
NCT05360446
Recruiting
CKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medication can effectively reduce the total amount of plaque formed in the heart's vessels as measured by coronary computed tomography angiography (CCTA) from baseline to month 24. This study is being conducted in eligible participants with a diagnosis of non-obstructive coronary artery disease (NOCAD), where the coronary arteries are blocked less than 50... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/04/2024
Locations: Heart Center Research Llc ., Huntsville, Alabama
Conditions: Coronary Artery Disease
Register for Updates
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
NCT05832151
Recruiting
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants wil... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Clinical Research Associates, LLC, Huntsville, Alabama
Conditions: Diabetic Gastroparesis
Register for Updates
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
NCT04609878
Recruiting
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
03/29/2024
Locations: Research Site, Huntsville, Alabama
Conditions: Asthma
Register for Updates
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
NCT05064540
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
All
Ages:
21 years and above
Trial Updated:
03/28/2024
Locations: Huntsville Hospital, Huntsville, Alabama
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Register for Updates